4. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) ranks fourth and offers something many small-cap biotech companies cannot yet show: real product revenue. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage dermatology biotech built around ZORYVE, its non-steroidal treatment portfolio. The company reported Q1 2026 net product revenue of $105.4 million, up 65% year over year, driven by demand for its dermatology treatments.
That revenue growth makes Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) one of the more straightforward commercial-stage biotech stories on this list. While many biotech companies depend on future trial readouts, Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) already has products in the market and growing demand. For investors searching for dermatology biotech stocks, commercial-stage biotech stocks, small-cap biotech stocks with revenue growth, and biotech stocks with approved products, Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) checks several important boxes.
The dermatology market is also larger and more commercially meaningful than some investors realize. Skin conditions can affect millions of patients, and treatments that offer convenience, safety, and long-term usability can gain meaningful traction. Non-steroidal options are particularly interesting because steroid-based treatments can carry limitations, especially for chronic use. That gives ZORYVE a clear position in a market where patients and physicians often want effective alternatives.
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) has the advantage of being easier to understand than many early-stage biotech companies. The company is not simply asking investors to believe in a distant future. It is showing revenue growth today. That does not remove risk, but it gives investors a more practical way to assess execution. They can track prescription trends, product revenue, gross-to-net dynamics, spending levels, and the company’s path toward profitability.
The Q1 2026 net product revenue figure of $105.4 million is important because it shows that Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is scaling. A 65% year-over-year increase is not small. It suggests that the company is gaining commercial traction in a competitive but attractive dermatology market. For small-cap biotech investors, this kind of growth can be more comforting than waiting on a binary FDA decision.
Of course, commercial-stage biotech comes with its own risks. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) still has to manage sales and marketing expenses, competition, payer coverage, patient access, and investor expectations. A fast-growing product can still disappoint if growth slows or if costs remain too high.
Still, Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) deserves its place near the top of this list because it combines a focused dermatology platform with real commercial momentum. For investors looking for biotech stocks with revenue growth, approved product biotech stocks, and small-cap healthcare stocks with a clearer business model, Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is one of the cleaner stories in the group.
Click next to see the following stock...
